📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 16:11
138 analysed today
FollowTelegram
138
Today
150,089
All-time analysed
43,015
Positive
6,671
Negative
91,681
Neutral
8,654
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
₹15 Cr Fundraise via Preference Shares and 460% Increase in Authorized Capital
Chemiesynth (Vapi) Ltd has approved a significant fundraise of ₹15 crore through the issuance of 5% Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) on a private placement basis to promoters or identified persons. This infusion is highly material, representing approximately 62.5% of the company's current market capitalization of ₹24 crore and 150% of its net worth. To accommodate this, the board is seeking shareholder approval to increase the authorized share capital from ₹3.25 crore to ₹18.25 crore. The preference shares carry a 5% cumulative dividend and have a 7-year tenure, providing long-term quasi-equity support to the loss-making entity.
Confidence: HIGH
What changedThe company is transitioning from a constrained capital structure to a significantly expanded one through a ₹15 crore promoter-led preference share issuance.
Why it mattersFor a micro-cap company with a ₹16 crore debt and recent losses (₹-1 crore TTM PAT), this ₹15 crore infusion is a critical liquidity event that could stabilize the balance sheet and fund future operations.
Fundraise Amount: ₹15,00,00,000Fundraise vs Market Cap: ~62.5%New Authorized Capital: ₹18,25,00,000Dividend Rate: 5% (Cumulative)Tenure: 7 YearsAGM Date: 2026-09-30
📅 Short termThe announcement of a large promoter-backed fundraise is likely to be viewed positively by the market as a sign of commitment, potentially supporting the stock price in the near term.
📈 Long termIf the capital is used to retire high-cost debt (D/E is currently 1.60) or fund growth, it could structurally improve the company's path to profitability; however, the 5% cumulative dividend remains a fixed obligation.
⚠ Risk flags
- Put option allows subscribers to demand redemption after 2 years, which could create future liquidity pressure.
- The preference shares are unsecured and unlisted.
- Dilution of preference in dividend payments over equity shareholders.
Key Highlights
Proposed issuance of ₹15 crore in 5% Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) to Promoter Group/Identified Persons.
Authorized share capital to be increased from ₹3.25 crore to ₹18.25 crore, a 461% increase.
Fundraise amount of ₹15 crore represents approximately 71% of the company's TTM revenue of ₹21 crore.
NCRPS tenure is fixed at 7 years with a 5% cumulative dividend, payable preferentially over equity shares.
Both Call and Put options are available after 2 years from the date of allotment.
👀 What to Watch
Monitor the upcoming AGM on September 30, 2026, for shareholder approval of the capital increase and the specific utilization plan for the ₹15 crore proceeds, particularly whether it will be used for debt reduction or capacity expansion.
₹15 Cr Fundraise via Preference Shares and Increase in Authorized Capital
Chemiesynth (Vapi) Ltd has approved a major fundraise of ₹15 crore through the issuance of 5% Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) on a private placement basis to promoters or identified persons. This infusion is highly material, representing approximately 62.5% of the company's current market capitalization (₹24 Cr) and 150% of its net worth (₹10 Cr). To facilitate this, the board has proposed increasing the authorized share capital from ₹3.25 Cr to ₹18.25 Cr. The preference shares carry a 7-year tenure with a 5% cumulative dividend, providing long-term capital to the specialty chemicals firm.
Confidence: HIGH
What changedThe company is initiating a significant capital infusion through preference shares, primarily targeting the promoter group, and expanding its capital base nearly six-fold.
Why it mattersFor a micro-cap company with a ₹24 Cr market cap and negative TTM PAT, a ₹15 Cr infusion is transformative. It provides a critical liquidity cushion and could significantly improve the debt-to-equity ratio (currently 1.60) if used for deleveraging.
Fundraise Amount: ₹15 CrFundraise vs Market Cap: 62.5%Fundraise vs Net Worth: 150%Authorized Capital Increase: ₹15 CrPreference Dividend Rate: 5% (Cumulative)Instrument Tenure: 7 Years
📅 Short termThe announcement of promoter-backed capital infusion is likely to be viewed positively by the market in the coming weeks, signaling support for the company's turnaround.
📈 Long termIf the capital is deployed toward growth or debt reduction, it could structurally improve the company's financial health over the next 2-7 years, though the cumulative dividend creates a fixed future obligation.
⚠ Risk flags
- Preference shares are cumulative, meaning unpaid dividends will accumulate as a liability.
- The Put Option allows subscribers to demand redemption after 2 years, potentially creating a liquidity risk.
- High debt-to-equity ratio of 1.60 prior to this infusion.
Key Highlights
Proposed fundraise of ₹15 crore via 5% cumulative preference shares on a private placement basis.
Authorized share capital to be increased by ₹15 crore, from ₹3.25 Cr to ₹18.25 Cr.
The fundraise amount of ₹15 Cr is equivalent to approximately 71% of the company's TTM revenue of ₹21 Cr.
Preference shares have a tenure of 7 years with a Put/Call option exercisable after 2 years.
40th Annual General Meeting (AGM) scheduled for September 30, 2026, to approve these proposals.
👀 What to Watch
Monitor the specific utilization of the ₹15 crore proceeds, particularly whether it is used to reduce the existing ₹16 crore debt or for capacity expansion. Investors should also review the detailed Q1 FY27 financial results once fully published to assess operational recovery.
₹15 Cr Fundraise via Preference Shares and Increase in Authorized Capital
Chemiesynth (Vapi) Ltd has approved a significant fundraise of up to ₹15 crore through the issuance of 5% Unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) on a private placement basis. This capital infusion is substantial, representing approximately 150% of the company's current net worth (₹10 Cr) and 62.5% of its market capitalization (₹24 Cr). To facilitate this, the board has proposed increasing the authorized share capital from ₹3.25 crore to ₹18.25 crore. The funds are expected to be sourced from the promoter group or identified persons, with a 7-year tenure and a 5% cumulative dividend.
Confidence: HIGH
What changedThe company is significantly expanding its capital base and seeking a ₹15 crore infusion via preference shares, primarily from promoters.
Why it mattersFor a micro-cap company with a ₹24 Cr market cap and recent losses, a ₹15 Cr infusion is a major liquidity event that could help stabilize its balance sheet (D/E is currently 1.60) and fund future growth.
Proposed Fundraise: ₹15 CrFundraise vs Net Worth: 150%Fundraise vs TTM Revenue: ~71%New Authorized Capital: ₹18.25 CrDividend Rate: 5% (Cumulative)Tenure: 7 Years
📅 Short termThe market is likely to view the promoter-backed fundraise as a sign of confidence, potentially supporting the stock price in the near term.
📈 Long termIf the capital is used to deleverage or pivot the loss-making operations (FY26 PAT was -₹0.99 Cr), it could structurally improve the company's financial health over the next 2-3 years.
⚠ Risk flags
- Cumulative dividend obligation adds a fixed financial burden even if the company remains loss-making
- The preference shares are unlisted and unsecured
- High reliance on promoter funding
Key Highlights
Proposed issuance of ₹15 crore in 5% Non-Convertible Cumulative Redeemable Preference Shares (NCRPS)
Authorized share capital to be increased by 461% from ₹3.25 crore to ₹18.25 crore
Fundraise amount of ₹15 crore is approximately 1.5x the company's current net worth of ₹10 crore
NCRPS carries a 5% cumulative dividend and a 7-year tenure with put/call options after 2 years
40th Annual General Meeting (AGM) scheduled for September 30, 2026, to seek shareholder approval
👀 What to Watch
Investors should monitor the upcoming Q1 FY27 results and the AGM proceedings for clarity on how the ₹15 crore will be utilized—specifically whether it will be used for debt reduction (current debt is ₹16 Cr) or business expansion.
Chemiesynth (Vapi) to consider Q1 results and Preference Share issuance on August 12
Chemiesynth (Vapi) Ltd has scheduled a board meeting for August 12, 2026, to approve its Q1 FY27 unaudited financial results. Crucially, the board will also consider a proposal to issue Unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) via private placement and an increase in Authorized Share Capital. This follows a fiscal year (FY26) where the company reported a net loss of Rs 0.99 Cr and carries a high Debt-to-Equity ratio of 1.60. Investors should also note the agenda includes approving Related Party Transactions with group companies and promoters.
Confidence: HIGH
What changedThe company is initiating a capital raise through preference shares and seeking approval for significant related party dealings alongside its quarterly results.
Why it mattersWith a small market cap of Rs 24 Cr and debt of Rs 16 Cr, the terms of this fundraise and the extent of promoter support are critical for the company's liquidity and financial stability.
Board Meeting Date: 12/08/2026Market Cap: Rs 24 CrDebt-to-Equity Ratio: 1.60TTM Revenue: Rs 21.44 CrDebt vs Market Cap: 66.6%
📅 Short termThe stock may react to the Q1 results and the specific details of the preference share issue announced on August 12.
📈 Long termThe capital infusion via NCRPS and the management of related party transactions will determine if the company can deleverage and return to consistent profitability.
⚠ Risk flags
- High Debt-to-Equity ratio (1.60)
- Related Party Transactions with promoters
- Issuance of unlisted preference shares may have complex terms
- History of net losses (Rs -0.99 Cr in FY26)
Key Highlights
Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results.
Proposal to issue Unlisted Non-Convertible Cumulative Redeemable Preference Shares (NCRPS) on a private placement basis.
Plan to increase Authorized Share Capital and amend the Memorandum of Association (MOA).
Approval of Related Party Transactions with Group Companies and Promoters scheduled for discussion.
Trading window remains closed from July 01, 2026, until 48 hours after the results declaration.
👀 What to Watch
Monitor the specific terms of the NCRPS issuance, including the coupon rate and redemption period, as well as the volume of Related Party Transactions relative to the company's Rs 21 Cr TTM revenue.
